Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Current Medical Research and Opinion

Volumn 30, Issue 11, 2014, Pages 2207-2216

  Bae, Jay P ^a   Faries, Douglas E ^a   Ernst, Frank R ^b   Lipkin, Craig ^b   Zhao, Zhenxiang ^a   Moretz, Chad ^b,c   Lieu, Hsiao D ^a   Effron, Mark B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Premier Healthcare Alliance   (United States)

^c HUMANA INC   (United States)

Author keywords

Acute coronary syndromes; Database; Outcomes assessment; Thienopyridine

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BARE METAL STENT; BLEEDING; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DRUG ELUTING STENT; FEMALE; HOSPITAL READMISSION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; HOSPITALIZATION; MIDDLE AGED; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA; STENT; STROKE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; STENTS; STROKE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84908611095     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.941055     Document Type: Article

References (27)

1. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-STelevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-81
2. OGara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425
3. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
4. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292
5. Jokhadar M, Jacobsen SJ, Reeder GS, et al. Sudden Death and recurrent ischemic events after myocardial infarction in the community. Am J Epidemiol 2004;159:1040-6
6. National Quality Measures Clearinghouse. Acute myocardial infarction: hospital 30-day, all cause, risk-standardized readmission rate (RSMR) following AMI hospitalization. Agency for Healthcare Research and Quality (AHRQ). Available at: http://www.qualitymeasures.ahrq.gov/content.aspx?id35575 [Last accessed 13 September 2012
7. Kolansky DM. Acute mortality coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care 2009;15(2 Suppl):S36-41
8. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360: 1418-28
9. Eisenstein EL, Cowper PA, Bae JP, et al. What is the clinical benefit of preventing non-fatal myocardial infarctions?. Value Health 2008;11:A341-2
10. Centers for Medicare &Medicaid Services. Outcomes Measures. Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/OutcomeMeasures.html [Last accessed 26 March 2013
11. Centers for Medicare &Medicaid Services. Premier Hospital Quality Incentive Demonstration. Available at: https://www.cms.gov/Medicare/ Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/ HospitalPremier.html [Last accessed 26 March 2013
12. Effient [package insert]. Indianapolis, IN: Eli Lilly and Company, 2013
13. Berenson K, Casciano R, Makenbaeva D, et al. Economic consequences of severe bleeding in patients with acute coronary syndrome in the USA. Adv Ther 2010;27:564-79
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
15. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
16. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24
17. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007;26:20-36
18. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303
19. Lawler PR, Filion KB, Dourian T, et al. Anemia and mortality in acute coronary syndromes: a systematic review and meta-Analysis. Am Heart J 2013;165:143-53.e5
20. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 2007;30(10 Suppl 2):II24-34
21. Steg, PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2001;32:1854-64
22. Damman P, Varenhorst C, Koul S, et al. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol 2014;113:64-9
23. Xanthopoulou I, Deftereos S, Sitafidis G, et al. In-hospital bleeding events in acute coronary syndrome patients undergoing percutaneous coronary intervention in the era of novel P2Y12 inhibitors: Insights from the Greek AntiPlatelet rEgistry-GRAPE. Int J Cardiol 2014;174:160-1
24. Wiviott SD, Desai N, Murphy SA, et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011;108:905-11
25. Wiviott SD, Antman EM, Gibson CM, et al; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-35
26. Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505-12
27. Thomas MR, Storey RF. Impact of aspirin Dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. J Cardiovasc Transl Res 2014;7:19-28